SynthesisInternational journal of chronic obstructive pulmonary disease2010
Association between lung function and exacerbation frequency in patients with COPD.
Synthesis in International journal of chronic obstructive pulmonary disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Pooled it
- Pooled it
- A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation.Health technology assessment (Winchester, England) · 2024Trial
- Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).Advances in therapy · 2015Trial
- Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Respiratory research · 2014Trial
- Factors associated with change in exacerbation frequency in COPD.Respiratory research · 2013Trial
- Longitudinal FEVInternational journal of chronic obstructive pulmonary diseaseTrial
- Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2025Article
- Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.Antibiotics (Basel, Switzerland) · 2024Review
- Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.The Lancet regional health. Western Pacific · 2024Article
- Association of blood cadmium concentration with chronic obstructive pulmonary disease progression: a prospective cohort study.Respiratory research · 2024Article
- DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.Advances in therapy · 2023Article
- Application of the Rome severity classification of COPD exacerbations in a real-world cohort of hospitalised patients.ERJ open research · 2023Article
- Article
- Article
- Current Chronic Obstructive Pulmonary Disease Treatment Status in Asia: A Position Statement of the Asian Pacific Society of Respirology.Tuberculosis and respiratory diseases · 2022Article
- Prediction of Chronic Obstructive Pulmonary Disease Exacerbation Events by Using Patient Self-reported Data in a Digital Health App: Statistical Evaluation and Machine Learning Approach.JMIR medical informatics · 2022Article
- Association of serum vitamin D levels with disease severity, systemic inflammation, prior lung function loss and exacerbations in a cohort of patients with chronic obstructive pulmonary disease (COPD).Journal of thoracic disease · 2021Article
- Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?The European respiratory journal · 2021Article
- A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.International journal of chronic obstructive pulmonary disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantify the relationship between severity of chronic obstructive pulmonary disease (COPD) as expressed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage and the annual exacerbation frequency in patients with COPD.
methodsWe performed a systematic literature review to identify randomized controlled trials and cohort studies reporting the exacerbation frequency in COPD patients receiving usual care or placebo. Annual frequencies were determined for total exacerbations defined by an increased use of health care (event-based), total exacerbations defined by an increase of symptoms, and severe exacerbations defined by a hospitalization. The association between the mean forced expiratory volume in one second (FEV(1))% predicted of study populations and the exacerbation frequencies was estimated using weighted log linear regression with random effects. The regression equations were applied to the mean FEV(1)% predicted for each GOLD stage to estimate the frequency per stage.
resultsThirty-seven relevant studies were found, with 43 reports of total exacerbation frequency (event-based, n = 19; symptom-based, n = 24) and 14 reports of frequency of severe exacerbations. Annual event-based exacerbation frequencies per GOLD stage were estimated at 0.82 (95% confidence interval 0.46-1.49) for mild, 1.17 (0.93-1.50) for moderate, 1.61 (1.51-1.74) for severe, and 2.10 (1.51-2.94) for very severe COPD. Annual symptom-based frequencies were 1.15 (95% confidence interval 0.67-2.07), 1.44 (1.14-1.87), 1.76 (1.70-1.88), and 2.09 (1.57-2.82), respectively. For severe exacerbations, annual frequencies were 0.11 (95% confidence interval 0.02-0.56), 0.16 (0.07-0.33), 0.22 (0.20-0.23), and 0.28 (0.14-0.63), respectively. Study duration or type of study (cohort versus trial) did not significantly affect the outcomes.
conclusionThis study provides an estimate of the exacerbation frequency per GOLD stage, which can be used for health economic and modeling purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.